Belatacept Pharmacokinetic Trial in Renal Transplantation

Completed · Phase 2

Conditions studied: Renal Transplantation

In brief

The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication

Key facts

Study ID

NCT00578448

Run by

Bristol-Myers Squibb

People needed

14

Starts

2008-03-01

Expected to finish

2012-09-01

Last updated by the study team

2014-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recipient of a living or deceased donor kidney
• First or second transplant
• Men and women, including women of childbearing potential, 18 years and older

You may not qualify if…

• Panel reactive antibodies ≥ 30%
• Significant infection

Where it is running

• Western New England Renal & Transplant — Springfield, Massachusetts, United States
• Henry Ford Hospital — Detriot, Michigan, United States
• Local Institution — Capital Federal, Buenos Aires, Argentina
• Local Institution — Aguascalientes, Aguascalientes, Mexico
• Local Institution — Cuernavaca, Morelos, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.